Jeff Yass’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Jeff Yass’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-83,121	Closed	-$1.53M	–	13225
2020 Q4	$1.53M	Buy	83,121 +48,897	+143%	+$891K	﹤0.01%	5704
2020 Q3	$628K	Buy	+34,224	New	+$575K	﹤0.01%	7197
2018 Q2	–	Sell	-43,028	Closed	-$755K	–	10760
2018 Q1	$755K	Buy	+43,028	New	+$788K	﹤0.01%	5801
2017 Q3	–	Sell	-36,573	Closed	-$320K	–	9959
2017 Q2	$320K	Buy	+36,573	New	+$322K	﹤0.01%	7475
2017 Q1	–	Sell	-24,584	Closed	-$322K	–	10409
2016 Q4	$322K	Buy	+24,584	New	+$329K	﹤0.01%	7837
2015 Q2	–	Sell	-21,270	Closed	-$669K	–	10623
2015 Q1	$669K	Buy	+21,270	New	+$575K	﹤0.01%	6578

Jeff Yass's CBMG Position: Q1 2021 in Review

Jeff Yass sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 83,121 shares — an estimated $1.53M sold.

Jeff Yass first reported a position in CBMG in Q1 2015 and held it in 6 quarters. The position peaked at $1.53M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

Jeff Yass reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
Jeff Yass sold 83,121 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $1.53M.
Jeff Yass first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 6 quarters.
Jeff Yass's Cellular Biomedicine Group, Inc. position peaked at $1.53M in Q4 2020.
0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.